Polyphor Ltd.. (6/27/19). "Press Release: Polyphor Appoints Frank Weber as New Chief Medical and Development Officer". Allschwil.

	Organisation	Polyphor Ltd. (SIX: POLN)
	Today	Spexis AG (SIX: SPEX)
	Group	Spexis (Group)
	Organisation 2	InterMune International AG
	Group	Roche (Group)
	Product	antibiotic
	Product 2	drug development
	Person	Weber, Frank (Polyphor 201901– CMDO before InterMune EU + Merck Serono + American Cyanamid/Lederle + Synthelabo + Merck)
	Person 2	Di Nepi, Giacomo (Polyphor 201611–202001 CEO before InterMune + Takeda + McKinsey RETIRED 1/20)

Polyphor AG (SIX: POLN) today announced the appointment of Frank Weber, M.D., as Chief Medical and Development Officer (CMDO), effective September 1, 2019. Dr. Weber, currently member of the Board of Directors, was supporting Polyphor as ad interim CMDO since January 1, 2019. Dr. Weber will leave the Board of Directors effective August 31, 2019.

Dr. Frank Weber has over 25 years of industry experience, with a strong scientific background and experience across all stages of product development, as well as clinical and operational expertise. He served as Senior Vice President, EU Medical and Global Medical Advisor of InterMune and prior to that as Chief Medical Officer at Merck Serono. Dr. Weber held also various clinical development medical positions at American Cyanamid/Lederle, Sythelabo and Merck KGaA and worked as a Medical Director in managed care with MedNet, a Munich Re/United Health Care joint venture. Dr. Weber trained as a maxillo-facial surgeon and immunologist. He holds a medical degree from the University of Cologne.

"I am truly pleased with the appointment of Frank Weber as our new CMDO. He has done an excellent job in his role as ad interim CMDO during the last 6 months, for which I would really like to thank him," commented Giacomo Di Nepi, Chief Executive Officer of Polyphor. "It is a great opportunity to work together with him again after the InterMune experience. He brings a wealth of clinical, scientific and strategic knowledge and a broad experience in different areas, including oncology, with the development of Erbitux at Merck, and antibiotics. I would also like to thank the Board of Directors for supporting Frank's move into his CMDO position."

"The Board of Directors would like to thank Frank for his great contribution and commitment to the Company. We are convinced that with his exceptional senior leadership track record, experience and business background he will bring the right skills' set to further develop the pipeline of the Company," said Dr. Jerry Karabelas, Chairman of Polyphor.

Dr. Weber will also join the Executive Committee as of September 1, 2019, which has just been complemented by Gökhan Batur, Chief Commercial Officer, succeeding Helmut Kessmann, who now reports to him.

For further information please contact:

For Investors:
Kalina Scott
Chief Financial Officer
Polyphor Ltd.
Tel: +41 61 567 16 67
Email: IR@polyphor.com

For Media:
Alexandre Müller
Dynamics Group AG
Tel: +41 43 268 32 31
Email: amu@dynamicsgroup.ch

About Polyphor

Polyphor is a clinical stage, Swiss biopharmaceutical company focused on the discovery and development of antibiotics and immuno-oncology compounds. It has discovered and is developing the OMPTA (Outer Membrane Protein Targeting Antibiotics). The OMPTA are potentially the first new class of antibiotics against Gram-negative bacteria to have reached phase III stage in the last 50 years. The company's lead OMPTA, murepavadin, (POL7080) is in Phase III development against Pseudomonas aeruginosa - recognized as a critical priority 1 pathogen by WHO; in addition, Polyphor is developing a pipeline of further preclinical antibiotics based on its OMPTA platform. Polyphor is also developing an immuno-oncology candidate, balixafortide (POL6326), which is starting a Phase III trial in combination with eribulin in patients with advanced breast cancer, and exploring in parallel its potential for further combinations and indications. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer

This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Record changed: 2023-06-05